

# WEEKLY VERSUS TWICE WEEKLY BORTEZOMIB GIVEN IN CONJUNCTION WITH RITUXIMAB IN PATIENTS WITH RECURRENT FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA AND WALDENSTRÖM MACROGLOBULINAEMIA

Athos Agathocleous, Ama Z Rohatiner, Simon Rule, Hannah Hunter, Jonathan Paul Kerr, Sally Neeson, Janet Matthews, Sandra Strauss, Silvia Montoto, P W M Johnson, et al.

# ► To cite this version:

Athos Agathocleous, Ama Z Rohatiner, Simon Rule, Hannah Hunter, Jonathan Paul Kerr, et al.. WEEKLY VERSUS TWICE WEEKLY BORTEZOMIB GIVEN IN CONJUNCTION WITH RIT-UXIMAB IN PATIENTS WITH RECURRENT FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA AND WALDENSTRÖM MACROGLOBULINAEMIA. British Journal of Haematology, 2010, 151 (4), pp.346. 10.1111/j.1365-2141.2010.08340.x hal-00580697

# HAL Id: hal-00580697 https://hal.science/hal-00580697

Submitted on 29 Mar 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# WEEKLY VERSUS TWICE WEEKLY BORTEZOMIB GIVEN IN CONJUNCTION WITH RITUXIMAB IN PATIENTS WITH RECURRENT FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA AND WALDENSTRÖM MACROGLOBULINAEMIA

Journal:	British Journal of Haematology
Manuscript ID:	BJH-2010-00725.R1
Manuscript Type:	Ordinary Papers
Date Submitted by the Author:	24-Jun-2010
Complete List of Authors:	Agathocleous, Athos; St Bartholomew's Hospital, CR-UK Medical Oncology Unit Rohatiner, Ama; St Bartholomew's Hospital, CR-UK Medical Oncology Unit Rule, Simon; Derriford Hospital, Department of Haematology Hunter, Hannah; Derriford Hospital, Haematology Kerr, Jonathan; Southampton General Hospital, CR-UK Clinical Centre Neeson, Sally; The University of Manchester and Christie NHS Foundation Trust, Medical Oncology Matthews, Janet; St Bartholomew's Hospital, CR-UK Medical Oncology Unit Strauss, Sandra; St Bartholomew's Hospital, CR-UK Medical Oncology Unit Montoto, Silvia; St Bartholomew's Hospital, CR-UK Medical Oncology Unit Johnson, P W M; Cancer Research UK Oncology Unit Radford, John; The University of Manchester and Christie NHS Foundation Trust, Medical Oncology Lister, T; St Bartholomew's Hospital, CR-UK Medical Oncology Unit
Key Words:	Bortezomib, Rituximab, B-cell malignancies
	۱ <u>ــــــــــــــــــــــــــــــــــــ</u>



WEEKLY VERSUS TWICE WEEKLY BORTEZOMIB GIVEN IN CON	JUNCTION WITH
RITUXIMAB, IN PATIENTS WITH RECURRENT FOLLICULAR LYMF	PHOMA,
MANTLE CELL LYMPHOMA AND WALDENSTRÖM MACROGLOBU	
Agathoclis, Agathocleous <sup>1</sup> , Ama Rohatiner <sup>1</sup> , Simon Rule <sup>2</sup> , Hannah Hu	nter <sup>2</sup> , Deleted: Athos
J.Paul Kerr <sup>3</sup> ,SM Neeson <sup>4</sup> , Janet Matthews <sup>1</sup> , Sandra Strauss <sup>1</sup> , Silvia M	Iontoto <sup>1</sup> , F Deleted: ¶
Johnson <sup>3</sup> , John Radford <sup>4</sup> , Andrew Lister <sup>1</sup> .	Deleted: ¶
<ul> <li>Kingdom.</li> <li>2. Department of Haematology, Derriford Hospital, Plymouth, United I</li> <li>3. CR-UK Clinical Centre, Southampton General Hospital, Southampt Kingdom</li> <li>4. The University of Manchester and the Christie NHS Foundation True</li> </ul>	ton, United
2. Department of Haematology, Derriford Hospital, Plymouth, United I 3. CR-UK Clinical Centre, Southampton General Hospital, Southampt	0
2. Department of Haematology, Derriford Hospital, Plymouth, United I 3. CR-UK Clinical Centre, Southampton General Hospital, Southampt	ton, United
<ol> <li>Department of Haematology, Derriford Hospital, Plymouth, United I</li> <li>CR-UK Clinical Centre, Southampton General Hospital, Southampt Kingdom</li> <li><u>The University of Manchester and the Christie NHS Foundation Tru</u></li> </ol>	ton, United <u>Ist, Manchester.</u> <b>Deleted:</b> Department of Med Oncology, Christie Hospital N
<ol> <li>Department of Haematology, Derriford Hospital, Plymouth, United I</li> <li>CR-UK Clinical Centre, Southampton General Hospital, Southampt Kingdom</li> <li>The University of Manchester and the Christie NHS Foundation Tru United Kingdom,</li> </ol>	ton, United <u>Ist, Manchester.</u> <b>Deleted:</b> Department of Med Oncology, Christie Hospital N
<ul> <li>2. Department of Haematology, Derriford Hospital, Plymouth, United I</li> <li>3. CR-UK Clinical Centre, Southampton General Hospital, Southamptor Kingdom</li> <li>4. The University of Manchester and the Christie NHS Foundation True United Kingdom,</li> </ul>	ton, United <u>Ist, Manchester.</u> <b>Deleted:</b> Department of Med Oncology, Christie Hospital N
<ul> <li>2. Department of Haematology, Derriford Hospital, Plymouth, United I</li> <li>3. CR-UK Clinical Centre, Southampton General Hospital, Southamptor Kingdom</li> <li>4. <u>The University of Manchester and the Christie NHS Foundation Tru</u> <u>United Kingdom</u></li> <li>Correspondence &amp; reprint requests:</li> <li>T. Andrew Lister</li> <li>CR-UK Medical Oncology Unit, St Bartholomew's Hospital</li> </ul>	ton, United <u>Ist, Manchester.</u> Deleted: Department of Mea Oncology, Christie Hospital N Trust, Manchester. United Kir Formatted: Font: (Default)
<ul> <li>2. Department of Haematology, Derriford Hospital, Plymouth, United I 3. CR-UK Clinical Centre, Southampton General Hospital, Southampt Kingdom</li> <li>4. <u>The University of Manchester and the Christie NHS Foundation Tru</u> <u>United Kingdom</u>,</li> <li>Correspondence &amp; reprint requests:</li> <li>T. Andrew Lister</li> </ul>	ton, United <u>Ist, Manchester.</u> Deleted: Department of Mea Oncology, Christie Hospital N Trust, Manchester. United Kir Formatted: Font: (Default)
<ul> <li>2. Department of Haematology, Derriford Hospital, Plymouth, United I 3. CR-UK Clinical Centre, Southampton General Hospital, Southamptor Kingdom</li> <li>4. The University of Manchester and the Christie NHS Foundation Tru- United Kingdom,</li> <li>Correspondence &amp; reprint requests:</li> <li>T. Andrew Lister CR-UK Medical Oncology Unit, St Bartholomew's Hospital 45 Little Britain,</li> </ul>	ton, United <u>Ist, Manchester.</u> Deleted: Department of Mea Oncology, Christie Hospital N Trust, Manchester. United Kir Formatted: Font: (Default)

1	
2	
3	
4	
5	
5 6	
7	
8	
9	
10	
11	
12	
17	
15	
16	
17	
18	
19	
11 12 13 14 15 16 17 18 19 20 21	
21	
22 22 23	
23	
24 25	
26	
27	
28	
29	
30	
31	
32	
33	
34 35	
36	
37	
38	
39	
40	
41	
42	
43 44	
44 45	
46	
47	
48	
49	
50	
51	
52	
53 54	
55	
56	
56 57 58	
58	

SUMMARY
The combination of bortezomib and rituximab was evaluated in
mantle cell lymphoma (MCL), follicular lymphoma(FL) and
Waldenström macroglobulinaemia (WM), in a Phase I and later, a
randomised Phase II study. In the latter, 42 patients with
recurrent/refractory disease received either: bortezomib 1.3mg/m2 on
days 1,4,8 and 11 of a 3-week cycle with rituximab 375mg/m2 on day
1,(21 patients) or: bortezomib 1.6mg/m2 and rituximab on days 1,
8,15 and 22 of a 5-week cycle (with rituximab being given only in
cycles 1 and 4). Twenty-eight patients were withdrawn (toxicity 16,
progression7, and 'patient choice' 5). The main toxicities were
neurological, gastro-intestinal and haematological. The overall response
rate was 28/42(67%) and by histology: MCL 11/19, FL 8/15, and WM
9/10. Ten of 28 responding patients remain progression-free at 1-3.5
years. Toxicity and efficacy were equivalent between the two
groups. The combination has significant toxicity but is effective,
particularly in patients with WM.
Keywords: bortezomib, rituximab, B-cell malignancies

Keywords: bortezomib, rituximab, B-cell malignancies

	Deleted: ¶ ¶
	Deleted: ¶ ¶
	Deleted: ¶ ¶
	Deleted: ¶
	Deleted: Summary 240 words ¶
	<b>Comment [A1]:</b> Suggest supplying the number of patients with each
	<b>Comment [A2]:</b> It might be more clear to say days 1, 4, 8, 11 of a 21-day cycle
	<b>Comment [A3]:</b> Same as previous comment: suggest providing the day# and total cycle length in days
	<b>Comment [A4]:</b> Do you mean more than one third of patients? Consider using a percentage rather than a fraction.
	<b>Comment [A5]:</b> This is a bit hard to follow: since the study is comparing arms, consider presenting results by arm instead of , or as well as, overall.
	<b>Comment [A6]:</b> This sentence should be clarified and split. Would clarify that the subsequent ratios just refer to response (not CR), and that the ratios by histology represent both groups combined.
	<b>Comment [A7]:</b> There's been no mention of the common or significant toxicities-suggest adding a sentence about them.
	<b>Deleted:</b> The proteasome inhibitor, Bortezomib, is active in follicular lymphoma (FL), mantle cell lymphoma (MCL) and Waldenström macroglobulinaemia (WM). Standard treatment for FL and MCL now includes rituximab. The combination was evaluated in a Phase I and subsequently a , randomised Phase II study. In the latter, 42 fForty-two patients with recurrent/refractory FL, MCL(19),FL(13), or WM (r10) received either: Bortezomib 1.3mg/m <sup>2</sup> on days 1,4.8 and 11 of a 21-day cyclex2/week, for two consecut [ [1]
1	Formatted: Font: (Default) Arial,

Formatted: Font: (Default) Aria Complex Script Font: Arial

**Formatted:** Font: (Default) Arial, Complex Script Font: Arial

**Formatted:** Font: (Default) Arial, Complex Script Font: Arial

Formatted: Font: (Default) Arial, Complex Script Font: Arial

**Formatted:** Font: (Default) Arial, Complex Script Font: Arial

**Formatted:** Font: (Default) Arial, Complex Script Font: Arial

Formatted: Font: (Default) Arial, Complex Script Font: Arial

- 2 -

#### INTRODUCTION

The concept of 'targeted' therapy, first proposed by Erhlich (1890) came to fruition in the management of malignant lymphoma with the demonstration of single-agent efficacy for the monoclonal antibody, anti-CD20 (rituximab) in B-cell malignancy. Most effective, and licensed originally for use alone, in follicular lymphoma (FL) (McLaughlin et al, 1998; Hainsworth et al, 2000 Hainsworth et al, 2002; & Witzig et al, 2005)), it also induces responses in mantle cell lymphoma (MCL) (Foran et al, 2000; Ghielmini et al, 2005 & Tobinai, 2002), and Waldenström macroglobulinaemia (WM) (Treon et al, 2001; Dimopoulos, et al 2002; Gertz et al, 2004 & Treon et al, 2005), The limited toxicity profile makes it an ideal partner for cytotoxic chemotherapy and 'chemo-immunotherapy' has now been shown to prolong not only freedom from recurrence but also survival in FL (Marcus et al, 2005; Hiddeman et al, 2005; Kropff et al, 2005; van Oers et al, 2007; Herold et al, 2007). Several studies in MCL have likewise shown a significant advantage for the addition of rituximab in terms of response rate, complete response rate and 'time to treatment failure' (Howard et al, 2002 & Lenz et al, 2005), but only one has thus far shown a survival advantage (Forstpointner et al, 2004).

The proteasome and in particular, the NF $\kappa$ B pathway is also a potentially attractive target in malignant lymphoma (de Martino *et al*, 1999 & Adams *et al*, 1999). A phase I study of the proteasome inhibitor, bortezomib in patients with refractory haematological malignancy identified a feasible dosing schedule, the most debilitating <u>clinical</u> toxicities being fatigue and

Deleted: M Formatted: Font: Italic Deleted: ,

Deleted: 4
Formatted: Font: Not Italic, Complex Script Font: Arial
Formatted: Font: Not Italic, Complex Script Font: Arial
Deleted: Kropff et al, 2005;
Deleted: 6

Deleted: ; Deleted: & Herold *et a*l, 2006 Deleted: mostly reversible, but sometimes painful, peripheral neuropathy; thrombocytopenia was also observed (Orlowski *et al*, 2002). Evidence of efficacy was most impressive in multiple myeloma but responses were also seen in FL, MCL and WM (Orlowski, *et al*, 2002).

In subsequent phase II studies, bortezomib was generally given twice weekly, at doses ranging from 1-1.6mg/m<sup>2</sup>. Activity was observed in patients with FL who had received multiple previous therapies (Di Bella *et al*, 2008; O'Connor *et al*, 2005 & Strauss *et al*, 2006) and in MCL, (O'Connor *et al*, 2005; Goy *et al*, 2005 & Strauss *et al*, 2006). However, a subsequent multi-centre trial (in MCL) suggested a rather lower response rate (31%), with a median duration of response of 9 months in a heavily pre-treated population (Fisher *et al*, 2006). Again, the principal toxicities were, gastro-intestinal tract symptoms, peripheral neuropathy and thrombocytopenia (O'Connor *et al*, 2005; Strauss *et al*, 2006; O'Connor *et al*, 2007; Goy *et al*, 2005; Fisher *et al*. 2006; Gerecitano *et al*, 2009 & de Vos *et al* 2009).

Bortezomib has also been shown to be highly <u>active in WM. On the</u> basis of *in vitro* data, using cell lines and cells from patients with WM (Mitsiades *et al*, 2003; Roccaro *et al*, 2007; Leleu *et al*, 2007), the drug was first used alone, in patients with recurrent or refractory disease. Unusually for such a patient population, 'major response' rates (Kimby *et al*, 2006) of >50% were observed (Treon *et al*, 2007; Chen *et al*, 2007; Dimopoulos *et al*, 2005 & Goy *et al*, 2005).

**Deleted:** peripheral neuropathy.

**Deleted:** Evidence of efficacy was most impressive in multiple myeloma but responses were also seen in FL, MCL and WM (Orlowski, *et al*, 2002). **Deleted:** ¶

Deleted: e as before,

Deleted: effective

Formatted: Font: Italic

- 4 -

On the basis of these preliminary results, a phase I/II randomised study of bortezomib given in conjunction with rituximab was initiated at <u>four</u>, hospitals in the United Kingdom. The objective was to compare <u>two</u>, different doses and schedules of administration of bortezomib in patients with recurrent and/or refractory FL, MCL and WM.

#### **DESIGN** AND METHODS

#### Study design

The protocol was approved by the Ethics Committees of the four participating hospitals; all patients gave informed consent. The study was carried out under the auspices of the NCRI Lymphoma Clinical Studies Group.

This was originally conceived as a phase I/II study, the objective of the phase I component being to determine the optimal weekly or twice-weekly dose of bortezomib when given in conjunction with rituximab. However, after the first 7 patients had been treated (in the Phase I component), in the light of data from a phase II study conducted in the United States, (Leonard *et al*, 2005) the protocol was amended to proceed directly to the randomised phase II component. The primary end points were: toxicity, which was monitored at each visit (using WHO criteria) and overall response rate. Secondary end points were freedom from progression and survival.

Deleted: In the latter and subsequent studies in other histological subtypes of lymphoma, thrombocytopenia and mostly reversible, but sometimes painful, peripheral neuropathy were identified as the major clinical problems associated with the drug (Orlowski et al, 2002; O'Connor et al, 2005; Strauss et al, 2006; O'Connor et al, 2007; Goy et al, 2005; Fisher et al. 2006; Gerecitano et al, 2009 & de Vos et al 2009). ¶

Deleted: 4

Deleted: 2

Deleted: PATIENTS

The total number of patients in the Phase II part of the study was based on the following considerations: assuming a 50% response rate to rituximab alone (from historical, control data), in order to demonstrate that the combination of bortezomib + rituximab was more effective than antibody alone, 20 patients were to be treated initially. If 16 responses were seen, a further 20 patients would be recruited. If between 7 and 15 responses were seen, a further 30 would be required. The planned interim analysis was duly conducted after 20 patients had been entered. On the basis of the safety and efficacy data, the decision was made to continue.

Response was assessed at the end of 4 cycles in arm A and after 3 cycles in arm B (please see below) and one month after completion of therapy. Patients deemed to have 'stable disease' completed planned therapy (unless withdrawn because of subsequent progression, toxicity or 'patient choice'). For patients withdrawn from the study for any reason, formal assessment of response was undertaken at the time of that decision.

#### Patients

Fifty patients were originally recruited, one withdrew before starting treatment and has therefore been excluded from the analysis. Thus a total of 49 patients, 7 in the phase I component and 42 in the phase II

- 6 -

#### **British Journal of Haematology**

form the basis of this report. Clinical characteristics at the time of study entry are shown in Table 1. Histological sub-types comprised: MCL: 21, FL: 17 and WM: 11. The median number of prior treatments was 2, range 1-7. Thirty-six of the 49 patients had bone marrow infiltration at the time of study entry; nine had previously received high-dose treatment supported by autologous peripheral blood progenitor cells.

#### Treatment

Phase I component: the first 7 patients were randomly allocated to receive bortezomib intra-venously (i/v), at the following doses: in Arm A: 0.7mg/m<sup>2</sup> (3 patients) and 1mg/m<sup>2</sup> (2 patients), twice weekly, or in arm B: 1.3me/m<sup>2</sup> (2 patients), weekly.

Phase II component: Forty-two patients were randomised to receive one of two different doses and schedules of administration as shown in Figure I. Arm A comprised: bortezomib given at a dose of 1.3mg/m<sup>2</sup> i/v, on days 1,4,8 and 11, of a 21-day cycle, to a maximum of 8 cycles, rituximab :375mg/m<sup>2</sup> being given on day 1. In arm B, bortezomib was given at a dose of 1.6mg/m<sup>2</sup> on days 1.5 and 22 of a 35-day cycle, to a maximum of 6 cycles. In order for the total dose of rituximab to be equivalent, the antibody was given on the same days as bortezomib but only in cycles 1 and 4 (i.e. a total of 8 infusions in both arms of the study)

Deleted: -1.3mg
Deleted: 2 and
Formatted: Not Superscript/ Subscript
Deleted: -1.3mg
Formatted: Superscript
Formatted: Superscript
Deleted: 2 and
Formatted: Not Superscript/ Subscript
<b>Comment [A8]:</b> Recommend specifying the actual dose levels, not just the range.
<b>Deleted:</b> 0-1.6
Formatted: Not Superscript/ Subscript
Formatted: Font: (Default) Arial, Complex Script Font: Arial
<b>Comment [A9]:</b> Same comment as in the summary "It might be more clear to say days 1, 4, 8, 11 of a 21-day cycle"
<b>Deleted:</b> twice weekly, i/v, for two consecutive weeks
Formatted: Font: (Default) Arial, Complex Script Font: Arial
Deleted: of each cycle.
<b>Deleted:</b> on the first day of four consecutive weeks of
Deleted: -week
Deleted: on
Deleted: days 1, 8, 15 and 22 of

- 7 -

#### <u>Definitions</u>

Standard response criteria were applied for patients with FL and MCL (Cheson *et al*,1999). Response in patients with WM was assessed using the Fourth International Workshop Criteria (Kimby *et al*, 2006). Progression-free survival is the interval between the date of assessment of response and evidence of progression. Overall survival is the interval from the time of commencing trial therapy until death or date of last follow-up.

## RESULTS

#### Phase I Component:

In general, toxicity was minimal, **however**, one patient with bone marrow infiltration at the time of starting treatment was withdrawn after the first cycle due to prolonged thrombocytopenia and concurrent progression. There was no evidence of response in the 6 other patients at the designated time of evaluation, although one patient with WM subsequently had a continuing decline in paraprotein from 26 to 10 g/L over a three year period, only having evidence of progression after a period of 4 years. Four of the 7 patients are alive, 2 having had further treatment.

- 8 -

## Deleted: Fig. 1¶

 $\begin{array}{l} \textbf{ARM A (total - 8 cycles)} \P \\ \textbf{Bortezomib: } 1.3mg/m^2 \quad i.v. \mbox{ or days} \\ 1, 4, 8 \& 11 \mbox{ of a 21-day cycle.} \P \\ \textbf{Rituximab : } 375mg/m^2 \quad i.v. \mbox{ infusion} \\ \textbf{on day 1 of each cycle} \P \end{array}$ 

ARM B (total - 6 cycles)¶ Cycles 1 and 4¶ Bortezomib:1.6mg/m<sup>2</sup> i.v. on days 1, 8, 15 and 22 of a 35-day cycle¶ Rituximab : 375mg/m<sup>2</sup> i.v. infusion ( on same days as above) Cycles 2, + 3,5 and 6. ¶ Bortezomib:1.6mg/m<sup>2</sup> i.v. on days 1, 8, 15 and 22, as aboveas above ¶ Cycle 4 Bortezomib:1.6mg/m<sup>2</sup> i.v. as above . . ¶ Rituximab: 375mg/m<sup>2</sup> i.v. inf. on same days as above Cycles 5 + 6 . Bortezomib:1.6mg/m<sup>2</sup> i.v. as abovabove¶ Definitions Formatted: Font: 12 pt, Complex Script Font: 12 pt Formatted: Line spacing: Double Formatted: Font: 12 pt, Complex Script Font: 12 pt Formatted: Font: 12 pt, Complex Script Font: 12 pt Formatted: Font: 12 pt, Complex Script Font: 12 pt Formatted: Font: 12 pt, Complex Script Font: 12 pt Formatted: Font: 12 pt, Complex Script Font: 12 pt Formatted: Font: 12 pt, Complex Script Font: 12 pt Formatted: Font: 12 pt, Complex Script Font: 12 pt Formatted: Font: 12 pt, Italic, Complex Script Font: 12 pt Formatted: Font: Italic

Formatted: Line spacing: Double

Phase II Component:

Formatted: Line spacing: Double

#### **British Journal of Haematology**

Following a satisfactory interim analysis of the results for the first 19 patients (one having been withdrawn prior to starting treatment), a further 23 were recruited.

## Clinical Toxicity (Table 2)

There were no deaths directly related to the therapy, although two patients died of infection after the blood count had recovered. Planned therapy was however completed in only 14/42 patients. Twenty-eight were withdrawn for the following reasons: toxicity:16, progressive lymphoma: 7 and 'patient choice': 5. Four of the patients in the latter group asked to be withdrawn because the found the side effects unacceptable.

The number of patients withdrawn from each arm of the study because of toxicity and the specific reasons for cessation of treatment according to arm are shown in Table III; they were approximately equivalent. Overall, grade 1 or 2 neurotoxicity was observed in 43% of patients treated twice weekly and 48% of those receiving treatment weekly. Grade 3 or 4 neurotoxicity (in most cases, painful neuropathy) developed in 14% and 19% of patients in the 2 groups respectively. In all cases it was reversible. Three patients were withdrawn from the trial because of gastro-intestinal (g/i) tract toxicity. Overall, grade I or 2 g/i toxicity was observed in 48% (nausea) and 52% (diarrhoea) patients receiving twice weekly treatment and patients and 62% of patients receiving bortezomib weekly. **Comment [A10]:** Should clarify what this means- Where there were intolerable AE's, were the unsatisfied with the responses, etc?

Formatted: Font: (Default) Arial, Complex Script Font: Arial Deleted: .

Deleted: all
<b>Comment [A11]:</b> What were the common manifestations of the G3-4 PN events?
Formatted: Font: (Default) Arial, Complex Script Font: Arial
<b>Comment [A12]:</b> Did this result in dose reductions or delays?
<b>Comment [A13]:</b> The "nausea and diarrhea" statement is more of an observation for the discussion
Formatted: Font: (Default) Arial, Complex Script Font: Arial
<b>Deleted:</b> Nausea and diarrhoea were also significant problems.
Formatted: Font: (Default) Arial, Complex Script Font: Arial

## Haematological toxicity (Table 2),

Grade I or 2 toxicity occurred in more than one third of patients, being observed equally in the two arms of the study. There was a trend for Grade 3 or 4 haematological toxicity to be more severe in arm A, in which bortezomib was given twice weekly, but no significant difference. Treatment was delayed in 14 patients, by 1-21 days, for various reasons but only in 2 cases because of neutropenia or thrombocytopenia.

Comment [A14]: As above-what about neuropathy? Formatted: Font: (Default) Arial, Complex Script Font: Arial

Response (Table 3)

The overall response rate was 28/42 (67%) with seven complete <u>responses</u> (CR) and 21 partial responses (PR) being observed. The response rate (CR + PR) was identical in the two treatment groups, namely, 14/21 (67%) in each arm. There was no significant difference in CR rate.

In terms of histological subtype, the response rates were, as follows, MCL: 11/19 (58%), FL: 8/15 (53%) and WM: 9/10 (90%). Twelve of the 14 patients who completed the planned therapy responded (3 CR, 9 PR), as did 16 (4 CR, 12 PR) of the 28 patients who did not complete treatment (7 because of disease progression). Sixteen of the latter 28 had been withdrawn because of toxicity, but 12/16 responded. (including 6/8 withdrawn specifically because of neuropathy) . In addition, four out of five patients withdrawn because of 'patient choice' had a PR.

Formatted: Line spacing: Double

Deleted: as

- 10 -

## Progression-free survival

Ten of the 28 patients who responded remain well without progression between 1 and 3.5 years. Four patients with WM remain asymptomatic without further treatment for between 2 and 2.5 years, five have progressed, (progression being defined as a >25% increase in the M band).

Overall Survival (Fig. 2)

Twenty-two of the original 42 patients remain alive, between 1.4 and 4 years, 10 without progression. Twelve patients have developed recurrent lymphoma but 10 of them remain well, (8 without further treatment and *2* having gone on to receive a reduced intensity allograft). Twenty patients have died, 16 following progression of lymphoma (8 having had further treatment. Four patients died without evidence of progression, 2 of pneumonia (one with a history of COPD), one of secondary acute myeloblastic leukaemia and one as a consequence of previous therapy. **Survival curves according to treatment arm are shown in Fig.2**,

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶
 ¶

 ¶</t

Deleted: ¶

Formatted: Line spacing: Double

**Formatted:** Font: 12 pt, Not Italic, Complex Script Font: 12 pt

**Deleted:** We are still looking into this (patient not at Barts).

#### DISCUSSION

These results, evaluating the combination of bortezomib and rituximab in B-cell malignancies show that the weekly and twice-weekly schedules,

Deleted:

- 11 -

designed to deliver the same total amount of both drugs yield the same results in terms of both toxicity and efficacy. Although outcome assessment was performed at somewhat different timepoints (the total duration of treatment being longer in Arm B), this is unlikely to confound the response rates since the discrepancy is only 6 weeks.

The results are in keeping with data from most other studies in which bortezomib has been combined with conventional chemotherapy in other settings (Barr *et al*, 2009, Ribrag *et al*, 2009; Sehn *et al*, 2009 & Leonard *et al*, 2005). One report has however suggested that when combined with rituximab, bortezomib is better tolerated and has greater efficacy when given weekly, to patients with recurrent or refractory follicular or marginal-zone lymphoma, (de Vos *et al*, 2009). Conversely, it was concluded in a phase II study of bortezomib given alone, weekly, (Gerecitano *et al*, 2009) that whilst the latter schedule was less toxic than twice-weekly bortezomib, (O'Connor *et al*, 2005) the overall response rate was inferior, with no complete remissions in patients with recurrent FL and MCL. Nonetheless, despite this, the considerably greater ease of giving treatment on a weekly basis provides a compelling argument for adopting this schedule in the future, certainly when the drug is being given in conjunction with rituximab.

Two recent Phase II studies using bortezomib in combination with bendamustine and rituximab, in patients with recurrent/refractory 'indolent' and mantle cell lymphoma (Friedberg *et al*, 2009), and

Deleted: both

Formatted: Line spacing: Double

Deleted:

#### Deleted:

**Comment [A15]:** I think this term sounds too casual for this article.

Deleted: 'patient friendliness' of

Deleted: the weekly schedule

**Formatted:** Font: (Default) Arial, Complex Script Font: Arial

- 12 -

#### British Journal of Haematology

specifically, recurrent follicular lymphoma (Fowler *et al*, 2009) have reported high response rates (79% and 86% respectively), with complete responses being observed in >50% of patients. Bortezomib has also recently been combined with 'CVAD' (Kahl *et al*, 2009) and 'R-CHOP' (Ruan *al*, 2009) in *newly-diagnosed* patients with mantle cell lymphoma with very high response rates and CR rates of >70%.

It is heartening for all three subtypes of lymphoma, that the results appear better than those reported in almost all studies for either drug given alone, in similar circumstances. Certainly, the combination warrants further evaluation. Particularly encouraging are the findings in the small number of patients with WM. Whilst no complete remissions were observed, partial responses were observed in 9/10 patients and 4 of the patients who responded continue well, transfusion-free without progression, between 2 and 2.5 years following completion of therapy. Similar results have recently been reported in two studies from the Dana Farber Cancer Institute (Ghobrial, in press, 2010, & Treon et al, 2009). In the first of these, in newly diagnosed patients, dexamethasone was included and in an illness where previously, complete responses were virtually never seen, a small number of patients entered CR and the 'major response' rate\_was 83%. A phenomenon specific to WM is reflected in the most recent classification of response in this illness (Kimby et el, 2006). It is now recognised that responses to Bortezomib when given in conjunction with had imab may occur late and may

Comment [A16]: Is the "I" a typo? Deleted: I (Ru Formatted: Font: (Default) Arial, Complex Script Font: Arial

Deleted:

Deleted: 2

Deleted: of	
<b>Comment [A17]:</b> This sentence be better broken into two.	might
Deleted: "	
Deleted: "	)
Deleted: ¶ ¶	
Formatted: Font: (Default) Aria Complex Script Font: Arial	əl,

 - 13 -

continue for several years, as was the case in one patient with WM treated in the Phase I component of the study.

Against this background, the toxicity of the treatment is of paramount importance. Whilst meaningful responses were observed in the majority of patients withdrawn from the study, for whatever reason, it is disturbing that only 14/42 patients were able to complete the planned therapy. A quarter developed 'intolerable' side effects, the most serious being painful peripheral neuropathy, and treatment was therefore stopped, without prior dose reduction. The incidence and severity of neuropathy were similar in the two groups of patients. Equivalent degrees of neurotoxicity have likewise been observed in other reports where bortezomib has been given once or twice weekly (O'Connor et al, 2005; Strauss et al, 2006; O'Connor et al, 2007; Goy et al, 2005; Fisher et al. 2006; Gerecitano et al, 2009 & de Vos et al 2009).

Even though largely reversible, as in myeloma (San Miguel *et al*, 2006), the neuropathy was, <u>distressing and debilitating for a significant</u> proportion of patients, as was the case for similarly pre-treated patients with lymphoma in another report (de Vos *et al*, 2009). Very close monitoring and asking patients specifically about symptoms of 'early' neurotoxicity, with appropriate treatment modification is mandatory and may reduce the severity of the problem (Richardson *et al*, 2006). **Comment [A18]:** Did patients receive dose reductions first, and then proceed to discontinuation, or were they just discontinued? Also, what were the inifestations (i.e., pain, others) leading the disc?

**Formatted:** Font: (Default) Arial, Complex Script Font: Arial

Formatted: Line spacing: Double

Deleted: verymost
Deleted: debilitating

- 14 -

It may be concluded that overall, these results give strong support to further investigation of bortezomib and rituximab in malignant lymphoma, particularly in patients with WM.

## Acknowledgements

This study was supported by a grant from Millenium Pharmaceuticals, who also kindly provided bortezomib for the study free of charge. We thank Hoffman-Ia-Roche for likewise providing Rituximab. We thank the referring physicians and the medical and nursing staff at the four hospitals for their expert care, Lynda Harrison and Nafti Lafon for help with data collection, and Elizabeth Hyde for preparing the manuscript.

## Authors' Contributions

TAL, AR, SR, PJ, and JR are the principal physicians, and take primary responsibility for the paper. AR and TAL wrote the paper. TAL, AR, SR, PJ, JR, AA, HH, SN, SS, and SM were involved in the care of the patients. AA and TAL compiled and analysed the data. All authors reviewed the manuscript.

## Conflicts of interest


JR has participated in Advisory Boards for MIllenium Pharmaceuticals and for Roche and is a stockholder of Glaxo-Smith-Kline (GSK). PJ has participated in Advisory Boards for GSK and for Roche, and receives research funding from Janssen Cilag and from Johnson and Johnson.

SR has participated in Advisory Boards for Roche and GSK and receives research funding from Johnson and Johnson.

Deleted: We thank the medical and
nursing staff at the four hospitals for
their expert care and Lynda Harrison
and Nafti Lafon for help with data
collection.

Formatted: Line spacing: 1.5 lines
Deleted: likewise
Deleted: and thanks
Deleted: the
Deleted: would also like to
Deleted: ,
Deleted: We are very grateful to
Deleted: ,
Deleted: ¶

{	Deleted: for
{	Deleted: s



Deleted: ¶

Table I. Clinical characteristics¶

Page 19 of 38

	▼	<b>- - •</b> -		<(	Deleted: 1
Patient Characteristics	Phase [ (7 pts.)	Phase <u>II</u> (42 pts.)	Pha Arm A (21 pts.)	se II Arm B (21 pts.)	Deleted: 2
Age, median (range)	54 (45-67)	60 (46-79)	60 (46-79)	61 (51-77)	Deleted: r¶
<b>Gende<u>r</u> Male <u>:</u> Female</b>	3 <u>:</u> 4	30 <u>:</u> 12	15:6	15:6	Deleted:     Deleted: /     Deleted: /     Deleted: /
Histological Subtype					Deleted: /
Mantle Cell lymphoma	2	19	9		Deleted:
Follicular Lymphoma	4	<del>-13</del>	6	7	Deleted: Formatted: Font: 12 pt, Not Bol
Waldenstr <u>ö</u> m Macroglobulinaemia	1	10	6	4	Deleted: 0
WHO Performance Status					Deleted:
19		22	11	++	Deleted:
	4	14	6	8	Deleted:
2	0	6	4	2	
── Serum LDH		<b>_</b>			Deleted: /
Normal : Elevated	4 <u>:</u> 3	21 : 21	9:12	12:9	Deleted: /
Stage		<u> </u>			Deleted: /
∪lage		A	<b>A</b>	<del>0</del>	Deleted:
' 	۱ ۹	3	U <b>1</b>	U	Deleted:
'''	U	7	<u>3</u>	<u> ۸</u>	Deleted:
III IN/	Ū		U	4	
IV	6 F	31	16	15 15	
Bone Marrow involvement	5	31	16	15	Deleted:
Number of Prior Treatments					Deleted:
Median (Range)					Deleted:
<u> </u>					Deleted:
2-3					Deleted:
>3	4	10	3	7	
High-Dose Therapy	4	5	2	3	

# Table II. Haematological and Clinical Toxicity (arm A vs. arm B)

Deleted:	_
Deleted:	4
	4
Formatted: Font: 12 pt, Bold	4
Formatted Table	4
Deleted: 21 pts.	4
<b>Deleted: ¶</b> 1.3mg/m <sup>2</sup>	_
Deleted: 21 pts.	
Deleted:	
<b>Deleted: ¶</b> 1.6mg/m <sup>2</sup>	
Formatted: Font: 12 pt	
Formatted: Font: 12 pt	
Deleted: ¶	
Deleted: ¶	
Formatted: Font: 12 pt	
Deleted: ¶	
Deleted: ¶	
Formatted: Font: 12 pt	-
Formatted: Font: 12 pt	<b>-</b>
Formatted: Font: 12 pt	<b>≺</b>
Formatted: Font: 12 pt	4
Formatted: Font: 12 pt	4
Formatted: Font: 12 pt	-
Formatted: Font: 12 pt	-
Deleted: )	-
Formatted: Font: 12 pt	-
Formatted: Font: 12 pt	~
· · · · · · · · · · · · · · · · · · ·	_

1
$\begin{smallmatrix} 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 1112 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 212 \\ 23 \\ 24 \\ 25 \\ 26 \\ 7 \\ 28 \\ 9 \\ 31 \\ 32 \\ 33 \\ 34 \\ 56 \\ 37 \\ 8 \\ 33 \\ 34 \\ 56 \\ 37 \\ 8 \\ 33 \\ 34 \\ 56 \\ 37 \\ 8 \\ 36 \\ 7 \\ 8 \\ 9 \\ 101 \\ 112 \\ $
3
1
5
5
6
1
8
9
10
11
12
13
11
14
10
16
17
18
19
20
21
22
23
20
24
25
26
27
28
29
30
31
32
33
24
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
52 53
53
54
55
56
57
58

Table III. Toxicity necessitating withdrawal from trial (Arm A vs. B)
---

Toxicity	Arm A	Arm B	Total
Neuropathy	5	3	8
GI	2	1	3
Haemorrhage	0	1	1
Chest infection	0	2	2
Cardiac	0	1	1
Fatigue & Lethargy	0	0	1
Total	8	8	16

Deleted: 2

Response	Arm A	Arm B	Total	 Formatted: Font: 12 pt
		Velcade 1.6mg/m <sup>2</sup>		 Formatted: Font: 12 pt
	x 2/week	Weekly	<u></u>	 Formatted: Font: 12 pt
CR	3	4	7	
PR	11	10	21	
'Stable Disease'	2	4	6	
Progression	5	5	10	
Total	21	21	42	
ORR	67%	67%	67%	

 Table V. Response rate according to histological subtype

 in Phase II component of trial

Response	Mantle Cell Lymphoma		Valdenström Iacroglobulinaemia		
CR	3	4	0		Formatted: Font: 12 pt
PR	8	4	9	12	Formatted: Font: 12 pt
Stable	.0	4	1		Formatted: Font: 12 pt
disease'	· · · · · · · · · · · · · · · · · · ·	······	<sup></sup>	$= \int_{-\infty}^{+\infty} h^{1/2}$	Formatted: Font: 12 pt
	0	0			Formatted: Font: 12 pt
Progression	8	3	0		Formatted: Font: 12 pt
<b>Fotal</b>	19	15	,10		Formatted: Font: 12 pt
				三板窓	Formatted: Font: 12 pt
					Formatted: Font: 12 pt
					Formatted: Font: 12 pt
					Formatted: Font: 12 pt
					Formatted: Font: 12 pt
					Formatted: Font: 12 pt
					Formatted: Font: 12 pt
				<sup>101</sup>	Formatted: Font: 12 pt
					Formatted: Font: 12 pt
				1	Formatted: Font: 12 pt
				'	Formatted: Font: 12 pt
Fig.	1. Treatment in P	hase II component of	trial		Formatted: Font: 12 pt
					Formatted: Font: 12 pt

# ARM A (total - 8 cycles)

Bortezomib: 1.3mg/m<sup>2</sup> i.v. on days 1, 4, 8 & 11 of a 21-day cycle.

Rituximab : 375mg/m<sup>2</sup> i.v. infusion on day 1 of each cycle

# ARM B (total - 6 cycles)

Cycles 1 and 4

Bortezomib:1.6mg/m<sup>2</sup> i.v. on days 1, 8, 15 and 22 of a 35-day cycle


Rituximab : 375mg/m<sup>2</sup> i.v. infusion (same days as above)

Cycles 2,3,5 and 6

Bortezomib:1.6mg/m<sup>2</sup> i.v. on days 1, 8, 15 and 22, as above

Fig.2

#### Survival of patients treated with Velcade & Rituximab



References

- 24 -

60

Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S., Elliott, P.J. (1999) Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents. Cancer Research, **59**, 2615-2622.

- Barr, P.M., Fu,P., Lazarus, H.M., Horvath, N., Gerson, S.L., Koc, O.N., Bahlis, N.J., Snell, M.R., Dowlati, A., Cooper, B.W. (2009) *Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma*. *British Journal of Haematology*, **147**, 89-96.
- Chen, C.I., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Wright, J.J., Powers, J., Walsh, W., & Eisenhauer, E.(2007) Bortezomib Is Active in Patients With Untreated or Relapsed Waldenstrom's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. *Journal of Clinical Oncology* **25**, 1570-1575.

Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, JM., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R., & Canellos, G.P. (1999) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. *American Society for Clinical Oncology*, **17**, 1244-1253.

de Vos, S., Goy, A., Dakhil, S.R., Saleh, M.N., McLaughlin, P., Belt, R., Flowers, C.R., Knapp, M., Hart, L., Patel-Donnelly, D., Glenn, M., Gregory, S.A., Holladay, C., Zhang, T., & Boral A.L. (2009) Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma. *Journal of Clinical Oncology*, **27**, 5023-5030.

De Martino, G.N. & Slaughter, C.A. (1999) The Proteasome, a Novel Protease Regulated by Multiple Mechanisms. *The Journal of Biological Chemistry*, **274**, 22123-22126,

Dimopoulos, M.A., Zervas, C., Zomas, A., Kiamouris, C., Viniou, N.A., Grigoraki, V., Karkantaris, C., Mitsouli, C., Gika, D., Christakis, J., Anagnostopoulos, N.. (2002) Treatment of Waldenstrom's Macroglobulinemia With Rituximab. *Journal of Clinical Oncology*, **20**, 2327-2333.

Di Bella, N., Taetle, R., Kolibaba, K.S., Boyd, T.E., Raju, R.N., Barrera, D.N., Cochran, E., Dien, P., Hakimian, D., Lyons, R.M., Schlegel, P.J, Vukelja, S.J., Boston, J., Boehm, K.A., Wang, Y., Asmar, L.(2010) Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. *Blood* **115**, 475-480. Deleted: ¶

**Formatted:** Font: 12 pt, Not Italic, Complex Script Font: Arial, 12 pt

#### Deleted: ¶

Field Code Changed

**Formatted:** Font: 12 pt, Complex Script Font: Arial, 12 pt

**Formatted:** Font: 12 pt, Complex Script Font: Arial

Formatted: Complex Script Font: Arial

**Formatted:** Font: Not Italic, Complex Script Font: Arial

Formatted: Font: Not Italic, Complex Script Font: Arial

Formatted: Font: Not Italic, Complex Script Font: Arial

Deleted: ¶

Formatted: Complex Script Font: Arial

Formatted: Font: Not Italic, Complex Script Font: Arial

Formatted: Border: Bottom: (Single solid line, Auto, 0.75 pt Line width)

Formatted: Complex Script Font: Arial

Formatted: Font: Not Italic, Complex Script Font: Arial

Deleted: ¶

Formatted: Complex Script Font: Arial

Deleted: ¶

**Formatted:** Font: Not Italic, Complex Script Font: Arial

**Formatted:** Complex Script Font: Arial

Formatted: Font: Not Bold, Complex Script Font: Arial

Formatted: Font: Not Bold, Complex Script Font: Arial

Deleted: ¶

Deleted: ¶

Formatted: Font: Not Bold, Italic, Complex Script Font: Arial Ehrlich, P. (1890) On immunity with special reference to cell life. *Proceedings of the Royal Society*.

Foran, J.M., Rohatiner, A.Z.S., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W.M., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A., Lister, T. Andrew. (2000) European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma *Journal of Clinical Oncology*, **18**, 317,

Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L., & Goy. A. (2006) Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology, 24, 4867-4874.

Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hänel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Böck, H., Wandt, H., Unterhalt, M., & Hiddemann W. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood* **104**, 3064-3071.

Fowler, Nathan, Kahl, Brad S, Rosen, Peter, Matous, Jeffrey, Cashen, Amanda, Jacobs, Samuel, Letzer, Jeffrey, Amin, Bipinkumar, Williams, Michael, Ross, Maureen, Smith, Sonali, Saleh, Alfred, Shi, Hongliang, Parasuraman, Sudha, Cheson, Bruce D. (2009) *Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.* ASH Annual Meeting Abstracts, **114**, 933.

Friedberg, Jonathan W., Vose, Julie M., Kelly, Jennifer L, Young, Faith, Liesveld, Jane, Armitage, James O., Proia, Nicole, Cruttenden, Kim, Leonard, John P. (2009) Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial. ASH Annual Meeting Abstracts, **114**, 924. Deleted: (2008) Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma, ASH Annual Meeting Abstracts, 112, 1572.¶

#### Deleted: ¶

#### Deleted: ¶

Formatted: Font: Not Bold, Complex Script Font: Arial

Formatted: Complex Script Font: Arial

Formatted: Font: Not Bold, Complex Script Font: Arial

Formatted: Font: Not Bold, Complex Script Font: Arial

#### Deleted: ¶

Formatted: Complex Script Font: Arial

Formatted: Complex Script Font: Arial

#### Deleted: ¶

**Formatted:** Normal, Border: Bottom: (Single solid line, Auto, 0.75 pt Line width)

Formatted: Font: (Default) Arial, Not Italic, Complex Script Font: Arial

Formatted: Font: (Default) Arial, Not Italic, Complex Script Font: Arial

#### Deleted: ¶

**Formatted:** Font: (Default) Arial, Complex Script Font: Arial

Formatted: Border: Bottom: (Single solid line, Auto, 0.75 pt Line width)

Deleted: ¶

Deleted: ¶

Formatted: Complex Script Font: Arial

**Formatted:** Font: Not Italic, Complex Script Font: Arial

Deleted: ¶

#### Deleted: ¶

Formatted: Complex Script Font: Arial

Formatted: Font: Not Italic, Complex Script Font: Arial

Deleted: ¶

Deleted: ¶

Deleted: ¶

Gerecitano, J., Portlock , C., Moskowitz, C., Hamlin, P., Straus, D.,

- 26 -

## **British Journal of Haematology**

Zelenetz, A.D., Zhang, Z., Dumitrescu, O., Sarasohn, D., Lin, D., Pappanicholaou, J., Cortelli, B.M., Neylon, E., Hamelers, R., Wright, J. & O'Connor, O.A. (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. *British Journal of Haematology*, **146**, 652-655

Gertz, M.A., Rue, M., Blood, E., Kaminer, L.S., Vesole, D.H., Greipp, P.R. (2004) Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An eastern Cooperative Oncology Group Study (E3A98). *Leukaemia and Lymphoma*, **45**, 2047-2055.

Ghielmini, M., Schmitz, S.H., Cogliatti, S., Bertoni, F., Waltzer, U., Fey, M.F., Betticher, D.C., Schefer, H., Pichert, G., Stahel, R., Ketterer, N., Bargetzi, M., & Cerny, T. (2005) *Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)*. *Journal of Clinical Oncology*, **23**, 705-711.

Ghobrial, I.M., Hong, F., Padmanabhan, S., Badros, A., Rourke, M., Leduc, R., Chuma, S., Kunsman, J., Warren, D., Harris, B., Sam, A., Anderson, K.C., Richardson, P.G., Treon, S.P., Weller, E., & Matous, J.(2010) Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia. Journal of Clinical Oncology, In press.

Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F., Rodriguez, A.M. (2005) *Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. Journal of Clinical Oncology*, **23**, 667-675,

Hainsworth, J.D., Burris, III, H.A., Morrissey, L.H., Litchy, S., Scullin, Jr, D.C., Bearden, III, J.D., Richards, P. & Greco F.A. (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. *Blood*, **95**, 3052-3056.

Hainsworth, J.J., Litchy, S., Burris III, H.A., *S*cullin Jr, D.C., Corso, S.W., Yardley, D.A., Morrissey, L., Greco, F.A. (2002) Rituximab as first line and maintenance therapy for patients with indolent Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology*, **20**, 4261-4267

Herold, M., Haas, A., Srock, S., Neser, S., Haifa Al-Ali, K., Neubauer, A., Dölken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Höffken, K., Franke, A., Jttel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Aßmann, M., von Grünhagen, U. (2007) Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, **25**,1986-1992,

Formatted	[ [2]
Deleted: ¶	[3]
Deleted: ¶	[4]
Formatted	( [5])
Deleted: .¶	<u> </u>
Formatted	
Deleted: ¶	<u>[ [6]</u>
Deleted: ¶	[7]
Deleted: ¶	<u>    (   [8]  </u>
Deleted: 1	( [9]
Deleted: Herold, M., Pasold	<u>,( [10] )</u>
Deleted: ¶	
Deleted: ¶	[11]
Formatted	[ [12] ]
Deleted: Antje	
Formatted	[13]
Deleted: Stefanie Sabine	[14]
Formatted	[15]
Deleted: Kathrin	
Formatted	[ [16]]
Deleted: Andreas	
Formatted	[17]
Deleted: Gottfried	]
Formatted	[18]
Deleted: RalphWolfgang	[19]
Formatted	[20]
Deleted: Mathias	
Formatted	[21]
Deleted: RobertKlaus	[22]
Formatted	[23]
Deleted: Astrid	
Formatted	[24]
Deleted: ThomasErika	[25]
Formatted	[26]
Deleted: Ursula	
Formatted	[27]
Deleted: Ulrich	
Formatted	[28]
Deleted: Christian Michae	<sup>l</sup> [[29]]
Formatted	[ [30]
Deleted: Ullrich	[31]
Formatted	[ [32]]
Deleted: ¶	
Formatted	[33]
Deleted: d	
Formatted	[34]
Deleted: ¶	
Formatted	[35]
Deleted: CO May 20 2007:	
Formatted	[36]
Deleted: ASH Annual Meeti	
Formatted	( [38])
Formatted	( [39])

[ ... [40]

... [41]

[... [42]]

[ ... [43]

... [44]

... [45]

[ ... [46]

[ ... [47]

[... [48]

... [49]

[ ... [50] ]

... [51]

... [52]

... [53]

... [54]

... [55]

<u>[... [56]</u>

Deleted: L

Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E.,	Deleted: Wolfgang
Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker,	Deleted: Martin
S. Fischer, T., Kropff, M., Reis, H., Freund, M., Wörmann, B., Fuchs, R.,	Deleted: Norbert
Planker, M., Schimke, J., Eimermacher, H., Trümper, L., Aldaoud, A.,	Formatted
Parwaresch, R. and Unterhal, M. (2005) Frontline therapy with rituximab	Deleted: Michael
added to the combination of cyclophosphamide, doxorubicin, vincristine,	Deleted: Eva
and prednisone (CHOP) significantly improves the outcome for patients	Deleted: Rudolf
with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German	Deleted: Marcel
Low-Grade Lymphoma Study Group, Blood, 106, 3725 - 3732,	Deleted: Bernd
	Deleted: Harriet
Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C.,	Deleted: Susanna
Janicek, M.J., Shipp, M.A. (2002) Rituximab and CHOP Induction	Deleted: Thomas
Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular	Deleted: Martin
Complete Responses Are Not Predictive of Progression-Free Survival.	Deleted: Hans-Edgar
Journal of Clinical Oncology, <b>20</b> , 1288-1294.	Deleted: Mathias
Kronff M. Dois H. Fround M. Wärmann P. Fusha P. Plankar M.	Deleted: Bernhard
Kropff, M., Reis, H., Freund, M., Wörmann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trümper, L., Aldaoud, A., Parwaresch, R.	Deleted: Roland
& Unterhalt, M. (2005) Frontline therapy with rituximab added to the	Deleted: Manfred
combination of cyclophosphamide, doxorubicin, vincristine, and	Deleted: Jörg
prednisone (CHOP) significantly improves the outcome for patients with	Deleted: Hartmut
advanced-stage follicular lymphoma compared with therapy with CHOP	Deleted: Lorenz
alone: results of a prospective randomized study of the German Low-	Deleted: Ali
Grade Lymphoma Study Group. <i>Blood</i> , <b>106</b> , 3725-3732.	Deleted: Reza
	Deleted: Michael
Kahl, B.S, Li, H., Smith, M.R., Gascoyne, R.D., Paietta, E., Advani, R.,	Formatted
Horning, S.J. (2009) The VcR-CVAD Regimen Produces a High	Deleted: t¶
Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 - A Phase II Study of VcR-CVAD with	Formatted
Maintenance Rituximab for MCL. ASH Annual Meeting Abstracts, 2009	Formatted
<b>114</b> ,1661.	Formatted
	Deleted: p¶
Kimby, E., Treon, S.P., Anagoostopoulos, A., Dimopoulos, M., Garcia-	Formatted
Sanz, R., Gertz, M.A., Johnson, S., LeBlond, V., Fermand, J.P., Maloney,	Formatted
D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R.,	Formatted
Stone, M., & Bladé, J. (2006) Update on Recommendations for	Deleted: od, Dec 2005;
Assessing Response from the Third International Workshop on	Formatted
Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma &amp; Myeloma</i> , <b>6</b> , 380-383.	Formatted
300-303.	Deleted: :
Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner,	Formatted
B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., Martin,	Deleted: ADD HIDDEMAN
S., Heidemann, E., Aldaoud, A., Parwaresch, R., Hasford, J., Unterhalt,	Formatted
M., Hiddemann, W. (2005) Immunochemotherapy With Rituximab and	Deleted: ¶
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone	Deleted: ¶
Significantly Improves Response and Time to Treatment Failure, But Not	Deleted: ¶
Long-Term Outcome in Patients With Previously Untreated Mantle Cell	Deleted: ¶
Lymphoma: Results of a Prospective Randomized Trial of the German	Deleted: ¶


- 28 -

1	
2 3 4 5 6 7 8 9	
3	
4	
5	
6	
/	
8	
9	^
1	0 1 2
1	ו ר
1	2 2
1	-2345678901234567890123456789
1	5
1	6
1	7
1	8
1	9
2	0
2	1
2	2
2	3
2	4
2	5
2	6
2	7
2	8
2	9
3	0
3	1
3	2
3	3
3	4
3	5
3	6
3	/ 0
ა ი	0
د ⊿	9
4	
-1	2
4	
4	-
4	
4	
4	
4	
4	
5	0
5	1
5	2
5	
	4
5	
5	6
5 5	7
-5	9

60

I

ow Grade Lymphoma Study Group (GLSG) <i>Journal of Clinical</i>	11-	Deleted: ¶ ¶		
JICOlogy, <b>23</b> , 1904-1992.		 Deleted: ¶		
eleu, X., Eeckhoute, J., Jia, X., Roccaro, A.M., Moreau, A., Farag, M.,	/	ſ		
Sacco, A., Ngo, H.T., Runnels, J., Melhem, Burwick, N., Azab, A., Azab, F., Hunter, Z., Hatjiharissi, E., Carrasco, D.R., Treon, S.P., Witzig, T.E.,		Formatted: Font: No Script Font: Arial	t Bold, Complex	
lideshima, T., Brown, M., Anderson, K.C & Ghobrial, I.M. (2007)		Formatted: Font: No Script Font: Arial	t Bold, Complex	
argeting NF-#B in Waldenstrom macroglobulinemia Blood,111, 5068-5077.		Deleted: ¶ ¶		
	/ (	Deleted: 4		
eonard, J.P., Furman, R.R., Cheung, Y. K., Feldman, E.J., Cho, H.J., 'ose, J.M., Nichols, G., Glynn, P.W., Joyce, M.A., Ketas, J., Ruan, J.,		Deleted: ¶ ¶		
Carew, J., Niesvizky, R., LaCasce, A., Chadburn, A., Cesarman, E.,		 Deleted: ¶		
Coleman, M.(2005) Phase I/II Trial of Bortezomib + CHOP-Rituximab in	141	¶		
Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase Results. ASH Annual Meeting Abstracts, <b>106</b> , 491.		Formatted: Complex Arial	Script Font:	
Aarcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J.,	1	Formatted: Font: Bo Script Font: Arial	ld, Complex	
Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A. & Smith,	(1) (1) (1)	Formatted: Complex Arial	Script Font:	
P. (200 <mark>5)</mark> CVP chemotherapy plus rituximab compared with CVP as first- ne treatment for advanced follicular lymphoma. <i>Blood</i> , <b>105</b> , 1417-1423.		Formatted: Font: Bo Script Font: Arial	ld, Complex	
IcLaughlin, P., Grillo-Lopez, J.A., Link, B.R., Levy, R., Czuczman, M.S.,		Formatted: Complex Arial	Script Font:	
Villiams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A.,		Deleted: ¶		
Cabanillas, F., Jain, V., Ho,A.D., Lister, J., Wey, K., Shen, D., Dallaire,		¶		
3.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy		Formatted: Font: (De Complex Script Font: /		
or relapsed indolent lymphoma: half of patients respond to a four-dose reatment program. <i>Journal of Clinical Oncology</i> , <b>16</b> , 2825-2833,		Formatted: Font: Bo Complex Script Font: <i>J</i>	ld, Not Italic,	
litsiades, C.S., Mitsiades, N., Richardson, P.G., Treon, S.P. & Anderson		Formatted: Font: No Complex Script Font: /	t Italic,	
K.C.(2003) Novel biologically based therapies for Waldenstrom's nacroglobulinemia. Seminars in Oncology, 30, 309-312.	, ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;	<b>Formatted:</b> Font: (Default) Arial, Complex Script Font: Arial		
D'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli,		Formatted: Font: (D Not Italic, Complex Sc	efault) Arial,	
B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E.,		Formatted: Font: (D Complex Script Font: /	efault) Arial,	
Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D., Zelenetz, A.D. (2005), <i>Phase II Clinical Experience With the Novel</i>		Formatted: Font: (De Not Italic, Complex Sc	efault) Arial,	
Proteasome Inhibitor Bortezomib in Patients With Indolent Non-Hodgkin's .ymphoma and Mantle Cell Lymphoma. Journal of Clinical Oncology, <b>23</b> , 1 576-684.		Formatted: Font: (D Bold, Not Italic, Comp Arial	efault) Arial,	
D'Connor, O.A., Hamlin, P., Moskowitz, C., Straus, D., Noy, A., Wright,		Formatted: Font: (De Not Italic, Complex Sc		
, Neylon, E., MacGregor-Cortelli, B., Portlock, C. & Zelenetz, A. (2007)		Deleted: ¶		
chedule of bortezomib administration may be an important determinant	()	Formatted	[57]	
f single-agent activity in patients with relapsed or refractory follicular	``{	Formatted	( [58]	
FL) lymphoma and mantle cell lymphoma (MCL). Journal of Clinical		Formatted	( [59]	
Dncology, ASCO Annual Meeting Proceedings, 25, 8051.	, (	Formatted	( [60]	
		Formatted	( [61]	
	$(\mathbf{x})$	Formatted	[ [62]	
	`۲	Deleted: ¶	[63]	



- 30 -

1
2
3
4
с С
7
8
9
10
11
12
13 14
15
16
17
2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 10 11 10 10 10 10 10 10 10 10 10 10 10
19
∠∪ 21
∠ ı 22
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
24
25
26
27
∠o 29
30
31
32
33
34
35
37
38
39
40
41
42 43
43 44
45
46
47 48
48
49 50
50 51
51 52 53
53
54
54 55 56
56
57 58
58 59
60

Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P., Lister, T.A. (2006) Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity, *Journal of Clinical Oncology*, **24**, 2105-211<u>2</u>.

Tobinai, K. (2002) Monoclonal Antibody Therapy for B-Cell Lymphoma: Clinical Trials of an Anti-CD20 Monoclonal Antibody for B-Cell Lymphoma in Japan. International Journal of Hematology, **76**, 411-419.

Treon S.P., Emmanouilides, C., Kimby, E., Kelliher, A., Preffer, F., Branagan A. R., Anderson, K. C., Frankel, S. R. (2005) Extended rituximab therapy in Waldenström's macroglobulinemia. *Annals of Oncology*, **16**, 132-138.

Treon, S.P., Agus, T.B., Link, B., Rodrigues, G., Molina, A., Lacy, M.Q., Fisher, D.C., Emmanouilides C., Richards A.I., Clark B., Lucas M.S., Schlossman R., Schenkein D., Lin B., Kimby E., Anderson K.C., Byrd J.C. (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. *Journal of Immunotherapy*, 24, 272-279.

Treon, S.P., Hunter, Z.R., Matous, J., Joyce, R.M., Mannion, B., Advani, R., Cook, D., Songer, J., Hill, J., Kaden, B.R., Sharon, D., Steiss, R., Leleu, X., Branagan, A.R., Badros, A. (2007) Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248. *Clinical Cancer Research*, **13**, 3320-3325.

Treon, S.P., Ioakimidis, L., Soumerai, J.D., Patterson, C.J., Sheehy,P., Nelson, M., Willen, M., Matous, J., Mattern, J., Jakow, J Diener, J.G., Keogh, G.P., Myers, T.J., Boral, A., Birner, A., Esseltine, D.L., & Ghobrial, I.M. (2009) Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180, *Journal of Clinical Oncology*, **27**, 3830-3835.

van Oers, M.H.J., Klasa, R., Marcus, R.E., Wolf, M., Kimby, E., Gascoyne, R.D., Jack, A., Mars van't Veer, A.V., Holte, H., van Glabbeke, M., Teodorovic, I., Rozewicz, C., & Hagenbeek A.(2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. *Blood*, **108**, 3295-3301, Deleted: 2.¶

Formatted: Font: Not Italic, Complex Script Font: Arial

Formatted: Complex Script Font: Arial

Deleted: ¶

Formatted: Font: Bold, Complex Script Font: Arial

Deleted: ¶

Formatted: Complex Script Font: Arial

**Formatted:** Font: (Default) Arial, Complex Script Font: Arial

**Formatted:** Complex Script Font: Arial, 12 pt, English U.S.

Deleted: ¶
Formatted: Normal

Formatted: Font: (Default) Arial,

Complex Script Font: Arial

Formatted: Default Paragraph Font, Font: (Default) Times New Roman, Complex Script Font: Times New Roman

#### Deleted: ¶

**Formatted:** Border: Bottom: (Single solid line, Auto, 0.75 pt Line width)

Deleted: ¶

Deleted: ¶

Deleted: ¶

Deleted: ¶

Deleted: ¶

**Formatted:** Border: Bottom: (Single solid line, Auto, 0.75 pt Line width)

- 31 -

Witzig, T.E., Vukov, A.M., Habermann, T.M., Geyer, S., Kurtin, P.J., Friedenberg, W.R., White, W.L., Chalchal, H.I., Flynn, P.J., Fitch, T.R. & Welker, D.A. (2005) *Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. Journal of Clinical Oncology*, **23**, 1103-1108.

Deleted: ¶

Deleted: ¶
Formatted: Font: Times New
Roman

Page 2: [1] Deleted Author The proteasome inhibitor, Bortezomib, is active in follicular lymphoma (FL), and Waldenström mantle cell lymphoma (MCL) macroglobulinaemia Standard treatment for FL and MCL now includes rituximab. (WM). The combination was evaluated in a Phase I and subsequently a, randomised Phase Il study. In the latter, 42 fForty-two patients with recurrent/refractory FL, MCL(19),FL(13), or WM [A1](r10) received either: Bortezomib 1.3mg/m<sup>2</sup> on days 1.4.8 and 11 of a 21-day cyclex2/week, for two consecutive weeks of a 21-day cycle<sub>IA21</sub> (maximum 8 cycles), with Rituximab 375mg/m<sup>2</sup> on day 1 (21 patients) or: Bortezomib 1.6mg/m<sup>2</sup> and Rituximab on days 1, 8,15 and 22 weekly for 4 weeks of a 35-day5-week cycle (maximum 6. Rituximab being given only in cycles 1 and  $4_{[A3]}$ ). Only 14Fourteen /42 patients completed therapy; 28 beingwere withdrawn (toxicity 16, progression 7, and 'patient choice' 5). The main clinical toxicities were neurologicalperipheral neuropathy and gastrointestinal. tract symptoms. Grade I/II haematological toxicity occurred in >33%. >1/3[A4]. The overall response rate was 28/42 (67%, i.e. 7), [A5]i.e.7 complete and 21 partial responses). Fourteen of 14/21 patients in each arm 21 partial responded; overall response rates by histology were: FL 8/15, : MCL 11/19, FL 8/15. and WM 9/10. [A6] Twelve of 14 patients who completed therapy responded. as did 16/28 withdrawnin whom the planned treatment was not .completeddid not. Ten of the /28 responding patients who responded remain progression-free( atfor between 1 -one and 1-3.5 years), 22/42 are alive, (atbetween 1.4 -and -4 years). The main toxicities were peripheral neuropathy and gastro-intestinal tract symptoms. There was no difference in Ttoxicity andor efficacy were equivalent between the two schedules. Thise combination has significant toxicity is toxic[A7] but is effective, and warrants further investigation, particularly in patients with WM.

# Keywords: Bortezomib, Rituximab, B-cell malignancies

Page 27: [2] Formatted	Author	
Complex Script Font: Arial		
Page 27: [3] Deleted	Author	
Page 27: [4] Deleted	Author	
Page 27: [5] Formatted	Author	
Page 27: [5] Formatted Complex Script Font: Arial	Author	
	Author Author	
Complex Script Font: Arial	Author	
Complex Script Font: Arial Page 27: [6] Formatted	Author	
Complex Script Font: Arial Page 27: [6] Formatted Font: Times New Roman, Comj	Author olex Script Font: 12 pt Author	

Font <sup>•</sup> (	(Default)	Arial	Not	Italic	Comr	lex	Scrip	t Font	Arial
I Ont. (	Derault	/ milai,	1101	mane,	COM	JICA	outp	ι I Onι.	minai

Page 27: [6] Formatted	Author	
Font: Bold		
Page 27: [7] Deleted	Unknown	
Page 27: [8] Deleted	Unknown	
Page 27: [9] Deleted	Author	
Page 27: [9] Deleted	Author	

Page 27: [10] Deleted

Herold, M., Pasold, R., Srock, S., Neser, S., Niederwieser, D., Neubauer, A., Dolken, G., Naumann, R., Fietz, T., Freund, M., Rohrberg, R., Hoeffken, K., Franke, A., Ittel, T.H., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., von Gruenhagen, U., Dachselt, K., Schwenke, H., Bleyl, D., Wolf, H., Hahnfeld, S., Hoffmann, F., Lakner, V., Richter, P., Hahling, D., Wolf, H. H., Eschenburg, H., Clemens, M.R., Grobe, N. (2004) Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

Author

Page 27: [11] Deleted

Author

## ADD REFERENCE FROM AMA MCL).

Herold et al became a paper in JCO, 2007 – GET REFERENCEASH Annual *Meeting Abstracts*, **104**, 584.

Herold, M., Haas, A., Srock, S., Neser, S., Al Ali, K.H., Neubauer, A., Doelken, G., Naumann, R., Fietz, T., Freund, M., Rohrberg, R., Hoeffken, K., Franke, A., Ittel, T.H. & Kettner, E. (2006) Addition of Rituximab to First-Line MCP (Mitoxantrone, Chlorambucil,

Prednisolone) Chemotherapy Prolongs Survival in Advanced Follicular Lymphoma - 4 Year Follow-Up Results of a Phase III Trial of the East German Study Group Hematology and Oncology

Michael

Page 27: [12] FormattedAuthorFont: (Default) Times New Roman, Bold, Complex Script Font: Times New Roman

Page 27: [12] Formatted

Author

Page 27: [12] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [12] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [13] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [14] Deleted	Author
Stefanie	
Page 27: [14] Deleted	Author
Sabine	
Page 27: [15] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [15] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [16] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [17] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [18] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [19] Deleted	Author
Ralph	
Page 27: [19] Deleted	Author
Wolfgang	
Page 27: [20] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [20] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [21] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [22] Deleted	Author
Robert	
Page 27: [22] Deleted	Author
Klaus	
Page 27: [23] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [23] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial
Page 27: [24] Formatted	Author
Font: (Default) Arial, Not Bold, Complex	Script Font: Arial

t Font: Arial t Font: Arial al
t Font: Arial
t Font: Arial
t Font: Arial t Font: Arial al
t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial al t Font: Arial al
t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial al t Font: Arial
t Font: Arial
t Font: Arial
t Font: Arial
t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial
t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial
t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial
t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial t Font: Arial
t Font: Arial t Font: Arial t Font: Arial al t Font: Arial t Font: Arial t Font: Arial
t Font: Arial t Font: Arial t Font: Arial al t Font: Arial t Font: Arial t Font: Arial
t Font: Arial al t Font: Arial t Font: Arial t Font: Arial al
t Font: Arial t Font: Arial al t Font: Arial t Font: Arial al
t Font: Arial al t Font: Arial t Font: Arial al
t Font: Arial al t Font: Arial t Font: Arial al
t Font: Arial al t Font: Arial t Font: Arial al
t Font: Arial al t Font: Arial t Font: Arial al
t Font: Arial al t Font: Arial t Font: Arial al
t Font: Arial al t Font: Arial t Font: Arial al
al t Font: Arial t Font: Arial al
al t Font: Arial t Font: Arial al
t Font: Arial t Font: Arial al
t Font: Arial t Font: Arial al
t Font: Arial al
t Font: Arial al
al
al
•
Script Font: Arial
t Font: Arial

Page 27: [39] [	Formatted Author
Font: (Default	) Arial, 12 pt, Complex Script Font: Arial, 12 pt
Page 28: [40]	Formatted Author
Font: (Default	t) Arial, 12 pt, Not Bold, Complex Script Font: Arial, 12 pt
Page 28: [41]	
Font: 12 pt, N	ot Bold, Complex Script Font: 12 pt
Page 28: [42] I	
	t) Arial, 12 pt, Not Bold, Complex Script Font: Arial, 12 pt
Page 28: [43] I	
	t) Arial, 12 pt, Complex Script Font: Arial, 12 pt
Page 28: [44] I	
	t) Arial, 12 pt, Not Bold, Complex Script Font: Arial, 12 pt
Page 28: [45] I Font: (Default	Author Author Author (Complex Script Font: Arial, 12 pt
· · · · · · · · · · · · · · · · · · ·	
Page 28: [46] I Font: (Default	Formatted         Author           (a) Arial, 12 pt, Not Bold, Italic, Complex Script Font: Arial, 12 pt
<b>Page 28: [47] I</b> Font: 12 pt, N	Formatted         Author           ot Bold, Complex Script Font: 12 pt
Page 28: [48]	
Font: (Default	t) Arial, 12 pt, Complex Script Font: Arial, 12 pt
Page 28: [49] I	
-	ot Bold, Complex Script Font: 12 pt
Page 28: [50] I	
	t) Arial, 12 pt, Not Bold, Complex Script Font: Arial, 12 pt
	Deleted Author MAN reference, CHOP VS CHOP + RITUXIMAB = BLOOD, 200
	VIAN TELETELE, CHOF VS CHOF + NT UNIVAB = BLOOD, 200
Page 28: [52]	Formatted Author
Font: (Default	t) Arial, 12 pt, Not Bold, Complex Script Font: Arial, 12 pt
Page 28: [53] I	Deleted Author
Page 28: [54] I	Deleted Author
Page 28: [55]	Deleted Author

Page 29: [57] Formatted	Author	
Font: (Default) Arial, Complex	x Script Font: Arial	
Page 29: [58] Formatted	Author	
Font: (Default) Arial, Not Itali	c, Complex Script Font: Arial	
Page 29: [59] Formatted	Author	
Font: (Default) Arial, Complex	x Script Font: Arial	
Page 29: [60] Formatted	Author	
Font: (Default) Arial, Not Itali	c, Complex Script Font: Arial	
Font: (Default) Arial, Not Itali Page 29: [61] Formatted	c, Complex Script Font: Arial Author	
Page 29: [61] Formatted	Author	
	Author	
Page 29: [61] Formatted Font: (Default) Arial, Complex	Author x Script Font: Arial Author	